GO
Loading...

Johnson & Johnson

More

  • More Tech Angst And Earnings Obsessions Tuesday, 23 Jan 2007 | 8:17 AM ET

    Stocks in the U.S. for now look headed to open flat to lower-- after yesterday's rocky trading. Europe is moving lower and oil is getting a lift from cold weather. Some big companies will roll out earnings reports today, to a market that has become hypersensitive to corporate earnings growth. Bank America, Johnson & Johnson and DuPont all report today.

  • FDA Scrutinizes Birth Control Drugs Tuesday, 23 Jan 2007 | 3:55 AM ET

    The government is considering setting higher standards for birth control drugs used by millions, saying that newer pills appear to be less effective at preventing pregnancy than those approved decades ago.

  • The drugmaker earned $9.45 billion in the fourth quarter, or $1.32 a share, compared with $2.73 billion, or 37 cents a share, a year earlier.

  • Pharma Picks: Rx For An Ailing Portfolio Tuesday, 26 Dec 2006 | 12:11 PM ET

    Wondering how to make big money in drug stocks next year? Two analysts told us their winning prescription for your 2007 portfolio on today’s “Morning Call.” Their advice: Look for (positive) newsmakers and buy into generics.

  • Dollars and Stents Friday, 22 Dec 2006 | 11:17 AM ET

    After the market close yesterday Pfizer, in an SEC filing, revealed that ousted Chairman and CEO Hank McKinnell will walk away with nearly $200 million in pension benefits, deferred compensation and other cash and stock including more than $300,000 in unused vacation time.  This is well above the pension benefits that had been reported earlier this year and includes money that had not previously been disclosed.  A Pfizer spokesman says the company is honoring its legal obligation to meet the terms of McKinnell's employment contract which was signed in 2001--"a different time in the company's history," he said.

  • Market Wrap: Stocks Slip Mostly On Weak Economic Report Thursday, 21 Dec 2006 | 4:53 PM ET

    Sellers outnumbered buyers on Wall Street after multiple reports signaled a slowdown in economic growth. CNBC's "Closing Bell" team sorted through the details.

  • All the major market indexes finished lower for the day.  Volume is likely to be light on Friday ahead of the Christmas holiday.

  • Boston Scientific has landed an exclusive contract to provide drug-coated stents to the Cleveland Clinic, one of the nation's most prominent cardiology centers, CNBC pharmaceuticals reporter Mike Huckman has learned.

  • CNBC's Huckman: Stent Battle Escalates Thursday, 21 Dec 2006 | 10:08 AM ET

    Within the last few hours CNBC's Pharmaceuticals Reporter Mike Huckman broke the news that Boston Scientific has locked up a huge account, but at what price?

  • FDA OK's New Version of Johnson & Johnson's Risperdal Wednesday, 20 Dec 2006 | 9:48 AM ET

    Invega, considered by some the most important drug in J&J's pipeline, will be marketed in the United States by the company's Janssen LP unit.

  • Stocks Close Modestly Higher Ahead of Fed Meeting Monday, 11 Dec 2006 | 4:55 PM ET

    Stocks posted modest gains across the board--with financial, technology and energy stocks showing strength.

  • Update On FDA Panel: No Change On Stent Labels Friday, 8 Dec 2006 | 4:09 PM ET
    FDA

    As we've been writing--CNBC pharmaceuticals reporter Mike Huckman has been reporting from Gaithersburg, Md--where the U.S. Food and Drug Administration has convened a panel to decide the fate of drug-coated stents. Johnson & Johnson and Boston Scientific – the two major producers of stents – have been eagerly awaiting a decision.

  • Greetings from the Gaithersburg, Maryland Hilton! That's where the FDA is holding the advisory committee meeting on the safety of drug-coated stents. For less high-profile FDA meetings this hotel and the Holiday Inn across the street (the FDA alternates between them) are just fine. But for a big meeting like this one the venue is way too small.

  • Drug-coated stents that buttress the arteries are safe when used as directed, health advisers say, even though the risks they may pose to the majority of patients with the devices remains an open question

  • Late Word on Stents--And Friday on cnbc.com Thursday, 7 Dec 2006 | 3:47 PM ET

    There's late word from CNBC's Mike Huckman. He reported in "Closing Bell' that the FDA stent conference came out in support of drug-coated stents. There had been concerns the drug-coated stents caused blood clots--and the metal stents did not. But the FDA says the proof is inconclusive.

  • Drug-coated stents that prop open the arteries of about 3 million people in the U.S. don't increase the risk of heart attack or death when used as labeled but may put patients at risk for blood clots, health advisers said Thursday.

  • FDA And Stents: Which Ones Are Safe? Thursday, 7 Dec 2006 | 1:39 PM ET
    FDA

    The U.S. Federal Drug Administration is right now weighing in on the heated debate over drug coated stents versus metal ones. Stents are implanted in patients to stop heart attacks. They're looking into evidence that drug-coated stents-- may lead to dangerous blood clots. It's a huge concern that's effecting millions of heart patients. It's also effecting the $5 billion dollar drug-coated stent industry.

  • J&J, Schering-Plough Halt Drug Trial Wednesday, 6 Dec 2006 | 2:33 PM ET

    Johnson & Johnson  has  suspended enrollment in a late-stage trial of an experimental rheumatoid arthritis drug it is co-developing with Schering-Plough because of short-term logistics problems.